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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is at present, the 
sixth leading cause of mortality and twelfth leading cause of morbidity 
worldwide. Smoking is one of the most important major risk factor 
leading to the development of COPD.  The risk of morbidity and 
mortality increases with both the quantum of smoking and duration in 
years.
 
Therefore the incidence of COPD can be prevented of if we do 
screening of the smokers without any respiratoy symptoms in their early 
age itself.  This can be achieved by doing spirometry in smokers.  
Spirometry measures the pulmonary function by measuring the air flow 
rates, lung volumes in the form of measuring FEV1, FVC, PEF 25 – 75% 
FEV1/ FVC.  It should be compared to their normal predicted values. 
If there is a decline in any of the above values, then the risk of 
occurrence of COPD in the near future can be assessed.  Patient can be 
advised to quit smoking, as cessation of smoking can halt the incidence 
and progression of the disease. 
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AIM OF STUDY 
1. To evaluate the pulmonary function test parameters in 
asymptomatic smokers. 
2. To compare the spirometric findings in asymptomatic smokers to 
their expected values. 
3. To identify the asymptomatic COPD among smokers, so that 
cessation of smoking would halt their progression. 
4. To identify the degrees of deterioration in PFT. 
5. To correlate the dysfunction with the quantum of smoking. 
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REVIEW OF LITERATURE 
Anatomy of the lungs:
35
 
  The respiratory system is made up of units for gas exchange (ie) 
the lungs and a pump which is necessary to ventilate the lungs.  The 
pump is made up of the wall of the chest, the muscles of respiration 
which can either increase or decrease the size of thoracic carity, the brain 
which has the central control over respiration.  
 At the rest, man breathes normally 12-15 times per minute.  Every 
time about 500ml of air enters the lung lion 6 lt/min of air is inspired or 
expired.  So 250ml of O2 enters the body and 200ml of Co2 is excreted 
from the body per minute.  
Air Passages : 
 The air passes through the nose, pharynx where it is warmed, then 
it pass down through trachea and bronchioles, respiratory bronchiolos, 
alveolar ducts and to the alveoli.  It is the alveoli, where gas exchange 
ocurs.  The first 16 generations are mainly concerned with the transport 
of gas from and to the exterior. They are constituted by bronchi, 
bronchioles and terminal bronchioles.  
 The remaining seven generations which forms the transititional and 
respiratory passages are concerned with gas exchange.  They are 
constituted by respiratory bronchioles, alveolar ducts and alveoli.  The 
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cross sectional area is increased form 2.5cm2 in trachea to 11,800 cm2 in 
alveoli due to these multiple divisions.  So, the velocity of the flow of the 
air is very much declined.  
Blood supply to the lungs : 
 All most, all the blood pass through the pulmonary artery which 
reaches the capillary bed. Here blood is oxygenated.  Then it returns to 
the left atrium of the heart through the pulmonary veins.  Bronchial 
arteries from systemic circulation also supplies the lungs.  
Mechanics of respiration :
34
 
 The lungs and chest wall are elastic structures.  Inspiration is an 
active process expiration is a passive process.  
Respiratory volumes and Capacities : 
1) Tidal Volume : 
 It is the amount of air which is inhaled or exhaled in one breath, 
while the person being relaxed and breathing quietly, normally, it is about 
500ml.  
2) Inspiratory Reserve Volume (IRV) : 
 Amount of air which can be inspired in excess of that tidal volume 
with a maximal inspiratory effort.  It is about 3000ml.  
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3) Expiratory Reserve Volume (ERV) : 
 It is the amount of air which is expired in excess to that of tidal 
expiration which can be exhaled with a maximal expiratory effort.  It is 
about 1200ml. 
4) Residual Volume (RV): 
 It is the amount of air which remains in the lungs after a maximum 
exhalation.   It is about 1200ml. 
5) Vital Capacity (VC) : 
 It is the amount of air which can be expired with a maximum effort 
after a maximum inspiration. (ie) ERV + TV + IRV. It is about 4700ml.  
6) Inspiratory Capacity (IC) : 
 It is the maximum amount of air that can be inspired after a normal 
expiration. It is about 3500ml.  
7) Functional Residual Capacity : 
 It is the amount of air that remain in the lungs after a normal 
expiration.  It is about 2400ml.  
8) Total Lung Capacity : 
 It is the maximum amount of air which the lung can accomodate. It 
constitutes about 5900ml.  
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SPIROMETRY 
Procedure  
 The test is performed in the sitting position and airflow is recorded 
as forced and sustained expiration followed by inspiration.3 efforts which 
have less than 5% variability between  each other are selected and the 
best effort is used for interpretation.  
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Spirometry Measurements:
4
 
FVC-Total volume of air exhaled with a maximal effort after deep 
inspiration. 
FEV1-Volume of air expired in the first second after deep 
inspiration. 
 
Other parameters are FEF25-75%,which is the midportion of 
expiration and vital capacity. 
Spirometry 
        Spirometry is the measurement of airflow during inspiration and 
expiration. It is  used to evaluate the pulmonary function in people with 
obstructive or restrictive lung diseases such as COPD, bronchial asthma, 
interstitial lung diseases etc. 
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Indications:  
 To confirm the presence or absence of respiratory disease in a 
person with signs or symptoms or presence of abnormal chest x –
ray or ABG. 
 To quantify the degree of known lung diseases. 
 To follow up the change in severity of the lung functions. 
 To assess the response to environmental and occupational 
response. 
 To assess the risk of surgical procedures which can affect the 
lungs. 
 To differentiate between obstructive and restrictive pattern of lung 
diseases. 
Contra indications: 
 Haemoptysis of unknown origin. 
 Pnemothorax. 
 Unstable cardiac status/ recent myocardial infarction. 
 Pulmonary embolism. 
 Thoracic,cerebral and abdominal aneurysm. 
 Recent cataract surgery.  
 Presence of any acute disease conditions. 
 Recent surgery done in abdomen or thorax. 
  
 
 
Complications: 
 Pnemothorax. 
 Raised intracranial t
 Syncope,light heade
 Chest pain. 
 Paroxysmal cough.
 Nosocomial infectio
 Bronchospasm. 
Normal Spirometric Valu
Parameters 
FVC (lt) 
FEV1 (lt) 
FEV1/FVC(lt/Sec) 
FEF 25-75% 
PEFR (lt / Sec) 
 
PATTERNS INTERPRE
TYPES
Obstructive 
Restrictive            
9 
ension. 
dness,dizziness. 
 
ns. 
es  
Predicted Normal  
Values 
% Predicted 
Baseline 
5 70% 
4 50% 
80 -- 
4 50 
8 75 
TED BY SPIROMETRY 
 FEV1 FVC FEV1/FVC
 /N  
           
  
/N 
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Smoking
16
 
Smoking is the practice of burning tobacco and inhaling the 
resulting smoke (consisting of particle and gaseous phases). It 
causesdamage to cells on the human body, no matter in which form it is 
packaged. However, it is said some forms of smoking tobacco are less 
harmful than others.  
Smoking in India : 
 30% of the population are 15 years or older in age group. 
 47% men and 14% of women—either smoke or chew tobacco. 
 Tobacco consumption was significantly higher in lower 
socioeconomic population. 
Types of Smoking Tobacco: 
I. Cigarettes: 
 Manufactured cigarettes are the most popular forms of smoking 
tobacco worldwide.  
 They are made by machine and put together using shredded or re-
used tobacco along with lots of different chemicals.  
 They also contain nicotine, which can make them very addictive. 
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II. Cigars: 
 Cigars are made up of tobacco that has been air-cured and 
fermented. The filling is held together in a wrapper that also made 
from tobacco. 
 Cigars can come in a variety of sizes, though generally they are 
bigger than cigarettes. They were previously thought of as an item 
smoked by wealthier, older men. 
 Trends have changed in recent years with much younger people, 
including women. 
 They are said to be a safer alternative to cigarettes because the user 
should not inhale when smoking a cigar, meaning no smoke 
reaches the lungs. 
 However, they are still a danger to a person's health and can still 
cause cancer in and around the mouth 
III. Pipe :
5 
 Pipe tobacco is normally a blend of tobaccos that may also contain 
different kinds of additives.                                                                   
 Pipes are made from a variety of different materials. The user 
places a flame directly onto the tobacco and smokes the fumes 
through a hole. 
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 They are also thought to be a safer alternative to cigarettes because 
the smoke does not have to be inhaled by the user.  
 However, cancer of the lip is more prevalent in pipe smokers than 
any other form of tobacco smoking. 
Bidis : 
 Bidis are the most popular form of smoking tobacco in India.  
 They have a only a small amount of tobacco, which is wrapped in 
dried temburni leaves.    
 They can come in either flavoured or unflavoured form and are 
imported into the United States from South Asia.  
 Bidis are said to have a higher concentration of tar and nicotine 
than manufactured cigarettes    
 The user usually has to smoke it harder to keep it alight.     
Chemicals  associated with smoking: 
30 
 The chemicals in cigarettes and tobacco smoke make smoking 
harmful. 
 Tobacco smoke contains over 4,000 different chemicals, at least 50 
are known to be carcinogens (cause cancer in humans) and many 
are poisonous.  
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CHEMICALS IN CIGARETTE 
Benzene (petrol additive)  
 A colourless agent which is a  cyclic hydrocarbon  and it is 
obtained from coal and petroleum.It is  used as a solvent for fuels 
and chemicals  which is present in cigarette smoker also.                                       
 It is a well known carcinogen which is associated with the 
development of leukaemia. 
Formaldehyde (embalming fluid) 
 A colourless liquid, which is highly poisonous,and it is used to 
preserve dead bodies by embalmation. – which is present in 
cigarette smoke. 
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 Known to cause carcinoma, respiratory, dermatological and 
gastrointestinal problems. 
Ammonia (Toilet Cleaner) 
 Used as a flavouring agent,can  liberate  nicotine from tobacco and 
turn it into a gas. 
 Most frequently seen in dry cleaning fluids. 
Acetone (Nail Polish Remover) 
 It is a fragrant volatile liquid which is a ketone, and used as a 
solvent, for example,  to remove nail polish. 
 Present in tobacco smoke. 
Tar 
 Particulate matter which can be drawn into lungs during inhalation 
from a lighted cigarette. After  inhalalation,in the lung of smokers, 
the tar  condenses more than 75 per cent and gets deposited in the 
respiratory tract . 
Nicotine (Insecticide/ Addictive Drug) 
 One of the most common addictive substances commonly amneble 
to man,which is  a powerful and fast-acting  poison. 
 This is the chemical commonly causing addiction in humans. 
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Carbon Monoxide (car exhaust fumes) 
 An odourless, tasteless gas which is a poisonous gas,and is rapidly 
fatal when inhaled in huge amounts. 
 The same gas is also produced in car exhausts 
 The main gas in tobacco smoke, formed when the cigarette is 
lighted. 
Diseases associated with smoking: 
16 
 Smokers frequently suffer from respiratory infections 
 Smoking affects almost all organs of the body. Smoking causes 
several diseases and detoriates the health of smokers . 
Smoking and Increased Health Risks
32
 
Compared with nonsmokers, smoking is estimated to increase the risk of 
 Increase in incidence of coronary heart disease by two to four 
times, 
 Increase in incidence of  cerebro vascular accidents by two to four 
times, 
 Males developing  bronchogenic carcinoma by twenty three times
,
 
 Females developing  bronchogenic carcinoma by thirteen times
,
 
and Death due to chronic obstructive lung diseases (such as chronic 
bronchitis and emphysema) by twelveto thirteen times.
1
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Smoking and  Diseases related to heart: 
 Cigarette smoking leads to reduction of circulation by occlusion of 
the  arteries and leads  to  increased risk of development of 
peripheral  arterial disease like gangrene of the extremities  that can 
lead to  symptoms like pain . 
 Smoking can lead to the development of aneurysm of the 
abdominal aorta (i.e., thinning of the arterial walls of the important 
vessel of the body - the aorta in its course through the abdomen). 
Smoking and Respiratory Disease 
 Smoking causes bronchogenic carcinoma. 
 Smoking causes respiratory diseases (e.g., emphysema, bronchitis, 
chronic airway obstruction) by destruction of  the airways and 
alveoli (i.e., small air sacs) of the lungs. 
Smoking and Cancer :
31
 
Smoking causes the following cancers: 
 Leukemias like AML. 
 Carcinoma of urinary bladder. 
 Cervical carcinoma. 
 Esophageal carcinoma. 
 Renal cell carcinoma. 
 Laryngeal carcinoma. 
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 Bronchogenic carcinoma. 
 Cancer of the cheek,tongue,lips.  
 Pancreatic carcinoma. 
 Pharyngeal carcinoma. 
 Stomach carcinoma. 
 Hepatocellular carcinoma 
Smoking and Other Health Hazards: 
Smoking has several deleterious effects during pregnancy and early 
childhood period, including increased risk for 
 Infertility, 
 Premature labour 
 Intrauterine growth retardation, 
 Stillbirth, 
 Birth weight lower than normal, and 
 Sudden infant death syndrome (SIDS). 
Smoking is associated with the following deleterious health effects: 
 Postmenopausal women with h/o smoking develop osteoporosis 
more frequently than women who had never smoked. 
 Women with h/o smoking will have an increased risk for fracture 
of hip joint.  
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Other Disease Associated with Smoking   
Acute coronary syndrome  
Coronary heart disease  
Cardiovascular disease  
Congestive cardiac failure  
Cerebrovascular disease  
Atherosclerosis  
 Aneurysm of the abdominal aorta. 
Bronchial asthma  
Diabetes mellitus 
Peptic ulcers  
Cataracts  
Gum disease  
Systemic hypertension  
Crohn's disease  
 
Peripheral artery disease  
Ischaemic heart disease  
Angina pectoris 
Haematopoietic cancers  
Emphysema  
Chronic bronchitis  
Pneumonia  
Premature aging of the skin  
Loss of smell and taste  
Decrease in bone density (women)  
Gangrene  
Impotence  
infertility  
   
  
 
 
19 
 
COPD 
In clinical practice, COPD is defined by its characteristically low 
airflow on lung function test. In contrast to asthma, this limitation is 
poorly reversible and usually gets progressively worse over time. 
It  includes all of the following  
1. Chronic bronchitis  
2. Emphysema  
3. Chronic airway obstruction  
4. Chronic non-specific lung disease  
5. Non-reversible obstructive airways disease  
6. Small airway disease( obliterative bronchiolitis) 
7. Cases of chronic asthma with fixed airway obstruction 
Risk factors 
2
 
Exposures  
1. Tobacco smoking 
2. Biomass solid fuel fires 
3. Coal miners and who work with cadmium  
4. Outdoor and indoor pollution  
5. Childhood infections and maternal smoking—affect lung growth 
reduce maximally attained lung function in adult life. 
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6. Recurrent infection – accelerate  decline in  FEV1.  Persistence of 
adenovirus in lung tissue alter local inflammatory response 
7. Low birth weight – reduce maximally attained lung function 
Host factors  
1. Genetic factor like alpha 1 – antiproteinase deficiency  
2. Airway  hyper-reactivity 
Cigarette smoking : 
 The major risk factor for mortality from chronic bronchitis and 
emphysema is cigarette smoking. There are numerous studies which show 
a significant reduction of FEV1 (ie) the volume of air exhaled within the 
first second of the forced expiration in a dose response relationship to the 
intensity of cigarette smoking which is expressed as pack years.  (average 
number of packs of cigarettes smoked per day multiplied by the total 
number of years of smoking.) Thus, cigarette smoking is a significant 
predictor of FEV1 which is very much declined in COPD.  
Pathology : 
2
 
 Cigarette smoke exposure can affect both large & small air way     
(< 2mm diameter) & alveoli. 
 Changes in large airways cause. Cough & Sputum. 
 Changes in small airways & alveoli are responisble for 
physiological alteration. 
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 Emphysema & small airway pathology – both are present in 
most persons with COPD.  
Large airway : 
 Smoking leads to mucous gland enlargement and goblet cell 
hyperplasia leading to cough and mucus production.  
 Bronchi can also undergo squamous metaplasia, predisposing to 
carcinogenesis and disrupting mucociliary clearance.  
 Neutrophil influx leads to purulent sputum production of upper 
respiratory tract infections.  
Small airways : 
 Major site of increased resitance in COPD is in airways < 2mm 
diameter.  
 Goblet cell metaplasia which replaces the surfactant secreting clara 
cells and infiltration of mononuclear phagocytes occur.  
 All these changes lead to luminal narrowing by fibrosis or collapse.  
Lung Parenchyma : 
 Emphysema is characterized by destruction of gas – exchanging 
air spaces ie – the respiratory bronchioli alveolar ducts and 
alveoli.  
 The walls of these airways perforate and later obliterate with 
coalescence into abnormal so much larger air spaces.  
  
 
 
 Macrophages accum
 Emphysema is class
1. Centriacinar emphyse
 Most frequent type
 Characterized by 
respiratory bronchi
 Most prominent in 
lobes.  
 Often quiet focal.
2. Panacinar Emphysema
 Abnormally large
across acinar unit
 Seen in patients w
 It has predilection
Pathogenesis :
19 
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Clinical features: 
31 
Pulmonary features  
 Chronic cough  --It is defined as cough  for at least 3 months in a 
year for 2 or more consecutive years  which may be intermittent or 
continuous during  the daytime. 
 If COPD is associated with cardiac failure,then dyspnoea occur 
more during nights  
 Sputum production –which is of either mucoid or mucopurulent  in 
nature. 
 It may be of copious amount in the early morning, especially on 
getting up from bed.  
 Dyspnoea develops during later course of the disease and 
progresses over time.  
 Breathlessness gets worsened on doing exercise and during acute 
exacerbations of the disease 
 Acute exacerbations of COPD 
 Repeated episodes of acute bronchitis leads to worsening of 
symptoms 
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Most patients would seek medical help only during these episodes 
of worsening .The systemic features are  
1. Muscular weakness  due to deconditioning and cellular changes in 
skeletal muscles 
2. Increased circulatory inflammatory markers 
3. Impaired sodium and water retention – peripheral oedema  
4. Altered lipid metabolism leading to weight loss 
5. Increased incidence of osteoporosis 
Physical examination :
2 
      Physical signs of pulmonary obstruction are rarely present until 
significant  detoriation of lung function has occurred 
1. Hyperinflated barrel shaped chest 
2. Pursed lips 
3. Prolonged expiration  
4. Central cyanosis  
5. Inward movements of lower ribs and intercostal indrawing 
during inspiration 
6. Palpation ---   cardiac apex not palpable 
7. Percussion ---  loss of cardiac dullness 
8. Hyper resonant chest 
9. Auscultation --- reduced breath sounds—wheeze  
10. Raised JVP , peripheral oedema if cor pulmonale 
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Severity of COPD  GOLD CRITERIA 
 
 
  
  
GOLD 
Stage 
Severity Symptoms Spirometry 
0   At Risk     Chronic cough, sputum 
production      
              Normal 
I   Mild   With or without chronic 
cough   
or   sputum production 
FEV1/FVC <0.7 and FEV1 80% 
predicted 
II Moderate With or without chronic 
cough or sputum production 
FEV1/FVC <0.7 and 50% 
FEV1<80% predicted 
III Severe With or without chronic 
cough or sputum production 
FEV1/FVC <0.7 and 30% 
 FEV1<50% predicted 
IV Very 
Severe 
With or without chronic 
cough or sputum production FEV1/FVC <0.7 and FEV1<30% 
predicted 
or 
FEV1<50% predicted with 
respiratory failure or signs of 
right heart failure 
Abbreviation: GOLD, Global Initiative for Lung Disease. 
Source: From RA Pauwels et al. 
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GOLD Executive Summary – updates 
The newly revised document emphasizes the following facts : 
1. COPD is characterized by chronic airflow limitation and a range of 
pathologic changes in the lung. 
2. The spirometric classification of COPD includes 4 stages.  
 Stage I – mild 
 Stage II – Moderate 
 Stage III – Severe 
 Stage IV – Very severe 
3. It recommends the use of fixed post – bronchodilator FEV, / FVC 
ratio of < 0.7 to  define airflow limitation.  But this can not be applied 
to elderly patients because the normal process of aging affects lung 
volumes. 
4. The Burden of COPD is about 15- 25% in adults of age more than 40 
years.  They  may show airflow limitation of stage I COPD or more 
than it.  
5. Cigarette smoking is a definite risk factor and elimination of this risk 
factor can prevent and control COPD.  
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6.
 COPD should be managed in four ways :
31 
 Assess and monitor disease. 
 Reduce the risk factors. 
 Manage stable COPD. 
  To manage acute exacerbations.  
7. Definition of Acute exacerbation “ An event in the natural course of 
the disease which is characterized by a change in the patient’s 
dyspnoea, cough, and / or sputum which is beyond normal day to day 
variations, which is acute in onset, and may indicate a change in 
regular medication in a patient with underlying COPD.  
 
Classical phenotypes  
Pink puffers  - Thin and breathless 
                      May over-ventilate 
              Maintain normal PaCO2 until the late stages 
Blue bloater    -   Tolerate / develop hypercapnia earlier  
                        Abundant purulent sputum 
           May develop oedema and secondary polycythemia 
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Comparison of Two Types of Chronic Obstructive  
Pulmonary Diseases. 
 
Predominantly 
Chronic Bronchitis 
(Blue – Bloater) 
Predominantly 
Emphysema  
(Pink – Puffer) 
Predominant 
Symptom 
Cough Dyspnoea 
Sputum Copious and purulent Scant and mucoid 
Episodes of bronchial 
infection 
More frequent Less frequent 
episodes of 
respiratory 
insufficiency 
Frequent Often terminally 
CXR 
Increased BV markings 
at lung bases, large 
heart  
Hyperinflation, bullous 
changes, small and 
tubular heart. 
Lung compliance Normal Increased. 
Airway resistance High 
Normal to slight 
increase.  
Arterial blood gases 
Abnormality early in 
course of disease. 
Normal until late 
Pulmonary 
Hypertension 
Moderate to severe None to mild 
Chronic Cor 
Pulmonale 
Common Rare  
Cardiac Failure common Rare 
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Complications of COPD :
31 
1. Pneumothorax : 
 The commonest cause for secondary spontaneous pneumothorax is 
COPD. It may be due to rupture of  a bleb or can occur during an acute 
exacerbation.  
 It leads to respiratory failure which is life threatening.  It should be 
treated as an emergency, since the condition is curable.  Treatment is by 
doing a Thoracostomy.  In patients with advanced COPD, recurrence is 
common.  So they should be treated b;y doing pleurodesis.  
Cor Pulmonale: 
 Chronic alveolar hypoxia leads to the development of Pulmonary 
hypertension, Right ventricular failure and consequently corpulmonale.  
Right heart failure signs appear later in the course.  After development of 
cor pulmonale, the median surrival period is diminished.  When the 
pulmonary artery pressure is more than 45mm of Hg, the average survival 
rate is diminished to less than 2 years.  
 The condition is treated with continous oxygen therapy for 
hypoxemia and diuretics for peripheral edema.  
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Supra ventricular Arrhythmias : 
It is common in COPD.   
Causes are due to  
1. Right atrial enlargement.  
2. Increased sympathetic tone.  
3. Hypoxemia. 
4. Iatrogenic due to drugs like theophyllire and ipratropium. 
Hypercapnia : 
 It is an adaptive response.  It is due to decreased work of breathing 
to reduce the fatiguability of respiratory muscles.  It leads to decreased 
sensation of breathlessness.  
 The adverse effects are alveolar hypoxia and pulmonary 
hypertension. 
 Treatment is to give oxygen in controlled concentrations with 
venturi masks.  
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Death in COPD : 
Due to 
1. Respiratory acidosis and coma  
2. Massive collapse of the lungs secondary to pneumothorax 
3. 3.Right heart failure. 
Investigations :
31 
 Two main investigations are X Ray chest and spirometry. 
A) X Ray chest : 
 There are 4 criterias to diagnose emphysema in chest X Ray.  They 
are  
a. The retrosternal space should be more than 2.54 cm in lateral 
radiograph. 
b. Hypertranslucency of pulmonary vessels. 
c. Low and flat diaphragm below 10
th
 posterior intercostal space.  
d. One or more bullae. 
 Atleast 2 Criteria should be present to diagnose COPD. 
B). Spirometric measurement of FEV1, and FVC is diagnostic of  COPD.  
 It also can  assess the severity and progression of the disease.  
 The hallmark of COPD is airflow obstruction.  
 Pulmonary function test shows airflow obstruction with a reduction 
in FEV1 and FEV1 / FVC. 
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 With worsening of the disease, lung volumes may increase, 
resulting in an increase in total lung capacity functional residual capacity 
and residual volume.  
 In patients with emphysema, the diffusing capacity will reduce, 
which reflects the destruction of the lung parenchyma. 
 The degree of airflow obstruction is an important prognostic factor 
in COPD.  
 More recently, a multifactorial index incorporating airflow 
obstruction, exercise performance dyspnoea and body mass index is a 
better predictor of mortality rate than spirometry abone.  
 Arterial Blood gases and oximetry can demonstrate resting or 
exertional hypoxemia.  
 The charge in PH with Pco2 is 0.08 units / 10 mm Hg acutely and  
0.03 units / 10 mm Hg in the chronic state.  
 Determination of arterial PH allows the classification of ventilatory 
failure, defined as Pco2 > 45mm Hg, into acute or chronic states.  
 Elevated haematocrit indicates the presence of chronic hypoxemia 
as does the presence of sign of right ventricular hypertrophy.  
 Computed Tomography is the current definitive test for 
establishing the presence or absence of emphysema.  
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 Recent guidlines suggest testing for ∝1 Antitrypsin deficiency in all 
persons with COPD with chronic airflow obstruction.  
Differential Diagnosis : 
1. Bronchial Asthma – 
 Usually the  patients are young, not a smoker with h/o atopy.  
Family members can have  similar illness – wheezing is the main 
complaint.  Broncho dilators andcortico   steroids give excellent relief. 
Corpulmonale is rare.  
2. Congestive Cardiac Failure: 
  B/L crepitations present on auscultation.  Chest X Ray may show  
cardiomegaly with pulmonary edema.  Spirometry shows volume 
restriction, but there will not be any airflow limitation.  
3. Bronchiectasis : 
 Copious amount of purulent sputum which is most frequently 
associated with bacterial infections. Coarse leathery crackles will be 
present on auscultation.  
4. Tuberculosis : 
 Can occur in all ages.  CXR will show lung infiltrates. Sputum 
have to examined for AFB.  
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5. Obliterative bronchiolitis: 
 Young  age of onset in non smokers. May give h/o rheumatoid 
arthritis  or exposure to fumes.  CT may show hypodense areas.  
6. Diffue panbronchiolitis : 
 Most patients are non smokers with h/o chronic sinusitis. CXR and 
HRCT shows diffuse small centrilobular nodular opacities and 
hyperinflation.  
Difference between Bronchial Asthma and COPD 
Bronchial Asthma COPD 
Patient is relatively young. Middle age or older. 
Non smoker Invariably smokers. 
H/o Atopy or family history Atopy is not essential. 
Inbetween symptom free. 
Symptoms are invariably persistent 
and more in winter. 
Wheezing is the main symptom 
Cough, sputum and dyspnoea are 
predominant symptom. 
Response to bronchodilators and 
sterodis – excellent. 
May not be excellent. 
Eosinophilia, sputum eosinophils 
and positive skin tsts. 
Unusual.  
Corpulmonale unusual Very common.  
Hypercarbia and Hypoxia – 
uncommon 
Common 
Reversibility to bronchodiators is 
charecteristic. 
Some reversibility present, but not 
more than 20% 
Diffusing capacity normal.  Low. 
Prognosis – usually good. Down hill course.  
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Excluding Alternate Diagnosis: 
 Tuberculosis should be excluded in all patients with complaints of 
chronic cough.  So sputum should be examined for AFB for a minimum 
of three times.  
 Other conditions like fibrocavitatory lesions of TB, bronchiectasis 
and mass lesions of lungs can be identified by chest X-Ray.  
 It can also diagnose the other complications like corpulmonale, 
pneumothorax and bronchopneumonia.  
 If  Bronchial Asthma is suspected, it should be ruled out by doing 
spirometry.  Bronchodilator  reversibility test is the best method to 
exclude bronchial asthma.  If spirometry is not available, PEFR with 
reversibility can be done.  
 Glucocorticoid reversibility test should be performed in patients 
with inadequate response to therapy or in patients with suspicion of 
asthma.  Oral prednisolone should be given for 2 weeks and spirometry 
should be repeated.  The criteria for reversibility are 
1. Increase in FEV1 by 200ml. 
2. Increase of 15% above baseline.  
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Confiming the Diagnosis : 
 The gold standard test for confirmation of COPD is spirometry.  It 
measures FVC, FEV1 and ration of FEV1/FVC.  The presence of post 
bronchodilator  FEV1 < 80% of the predited value in combination with 
FEV1 / FVC ratio < 70% confirms the presence of air flow limiation 
which is not fully reversible.  
Treatment:
31 
a. A.Non pharmacological method 
 
 Cessation of smoking 
 Avoiding precipitating factors 
 Pulmonary rehabilitation 
b. Pharmacological method 
 Bronchodilators  
 Corticosteroids 
 Theophylline and aminophylline 
c. Surgical intervention  
 Bullectomy 
 Lung volume reduction surgery  
 Lung transplantation 
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d. Others  
 Offering vaccination 
 Palliative care 
Smoking cessation : 
 It can be attained by  
1. Non pharmacological  
2. Pharmacological 
Non pharmacological 
 Educating the patient about the hazards of smoking 
 Group counselling  
 Hypnosis  
Drug therapy: 
 Nicotine replacement therapies --  in the form of transdermal 
patch , lozenges etc. 
 Bupropion; 
 Nicotine replacement therapyavailable as gum, transdermal 
patch, inhaler, and nasal spray; and 
 Varenicline a nicotinic acid receptor agonist/antagonist 
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Avoidance of precipitating factors 
 Masks can be weared at work place where dust is generated. 
 Use of water to suppress dust 
 Avoiding open burning of crop residue 
Drug treatment : 
a. Bronchodilators :
31
 
 It is central and most important drug used in  the symptomatic 
management of COPD. 
 Inhaled drugs are usually preferred to oral preparations. 
 Short acting bronchodilators can be used prophylactically to relieve 
intermittent or worsening symptoms and when used on regular basis it 
can  prevent or reduce the severity of persistent symptoms. 
 Regular treatment with short-acting bronchodilators is even though 
cheaper but it is less convenient for usage than  long-acting 
bronchodilators 
 The long acting inhaled beta agonist salmeterol  can improve the 
symptoms significantly in doses of 50µg twice daily 
 In addition if theophylline is given along with  bronchodilators or 
anticholinergics (ipratropium bromide and tiotaropium)  it may give an 
additional improvement. 
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Step by Step pharmacological therapy : 
I. Mild, variable symptoms : 
 Selective Beta – 2 agonist metered dose inhaler (M D I) aerosol, 1 - 
2 puffs    every 2 – 6 hours as needed.  Maximum dose 8 – 12 puffs over 
24 hours.  
II. Mild to moderate continuing symptoms : 
 Ipratropium MDI aerosol  
 2 to 6 puffs / 6 – 8
th
 hourly. 
 Plus Selective Beta 2 agonist 
 MDI aerosol 1- 4 puffs / 6
th
 hourly.  
III. If no response : 
 Add sustained release theophylline, 200 – 400mg b.d or 400 – 
800mg at bed time for nocturnal broncho spasm And / or  Sustained 
release salbutamol 4 – 8mg bd or bed time only. Mucolytics can be 
added.  
IV. If control of symptoms are not optimal : 
 Course of prednisolone 40mg / day for 10 14 days.  
 If improvement occurs, taper the drug.  
 If no improvement, it can be stopped abruptly and inhaler 
steroid should be considered.  
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V. Severe acute exacerbation : 
 Increase β2 agonist dose (MDI with spacer 6-8 puffs every ½ - 2 
hours or subcutaneous injection of adrenaline or salbutamol or terbutaline 
in the dose of  0.1 – 0.5 ml. And / or 
 Increase ipratropium dosage (MDI) 6-8 puffs / 3-4
th
 hourly or 
inhalation  every 4-8 hours and Intravenous theophylline to make serum 
level of 10-12 mg /ml and Intravenous methyl prednisolone 50-100mg, 
repeated 6-8 15 hourly should be tapered as early as possible and 
hydrocortisone should be substituted. Add Antibiotics and mucolytics if 
indicated.  
b. Corticosteroids 
 Inhaled corticosteroids cannot change the rate of decline in 
pulmonary function, but can  
 increase postbronchodilator FEV1 
 reduce the number of  occurrence of acute exacerbations 
 slow the rate of decline in morbidity. 
It is indicated for   
 patients with a documented evidence of spirometric response of 
reversibility to glucocorticosteroids 
 FEV1<50% of the predicted value. 
 Patients with frequent acute severe exacerbations 
Their use has been associated with several side effects like 
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increased rates of oropharyngeal candidiasis and an increased rate of 
osteoporosis. 
Common side effects : 
 Loss of bone mineral density, 
 weight gain, 
 cataracts of the lens, 
 glucose intolerance,  
  risk of  serious and recurrent infection, 
     If the dose of steroids are reduced and tapered to less thas 
10mg/day,then the side effects can be minimized. 
c. Oxygen  
 Supplemental O2 is the only pharmacologic therapy demonstrated 
to unequivocally decrease mortality rates in patients with COPD.  
 For patients with resting hypoxemia (resting O2 saturation 88% or 
<90% with signs of pulmonary hypertension or right heart failure),    
the use of O2 has been demonstrated to have a significant impact on 
mortality rate 
 Patients meeting these criteria should be on continual oxygen 
supplementation, as the mortality benefit is proportional to the 
number of hours/day oxygen is used.  
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Exacerbations of COPD:
31
 
   Exacerbations are a prominent and quiet often feature seen 
frequently  in the natural history of COPD. 
  Exacerbations are  frequent episodes associated with increased 
breathlessness and cough with change in the amount and character 
of sputum. 
  Sometimes they are associated with fever, sore throat and malaise. 
  The frequency of exacerbations increases as airflow obstruction 
increases; 
  Patients with moderate to severe airflow obstruction [GOLD 
stages III, IV (Table 260-1)] on average have one to three episodes 
per year. 
  However, some individuals with very severe airflow obstruction 
do not have frequent exacerbations; 
  The history of prior exacerbations is a strong predictor of future 
exacerbations. 
Indication for hospitalization of COPD :  
Hospitalization : 
1. Acute exacerbation with one or more of the following : 
 Inadequate response to outpatient management. 
 Inability to eat or sleep due to dyspnoea.  
 Inability to walk between rooms. 
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 When patient cannot be managed at home.  
 High risk comorbid conditions. 
 Altered sensorium. 
 Worsening hypoxemia.  
 New or worsening hypercarbia. 
2. New or worsening of corpulmonale which is unresponsive to 
outpatient management.  
3. During surgery which require sedatives that may worsen the lung 
function.  
4. Comorbid conditions like severe steroid induced myopathy, 
compression fracture of the vertebra which can worsen the lung 
functions.  
ICU Admission : 
1. Severe dyspnoea that do not respond adequately to initial 
emergency therapy.  
2. Confusion, lethargy or respiratory muscle fatigue.  
3. Persistent or worsening hypoxemia inspite of O2 therapy.  
4. When mechanical ventilation is required.  
5. General approach to management of COPD : 
6. Establish the diagnosis and assessment of symptoms.  
7. Cessation of smoking should be achieved completely.  
  
 
 
46 
 
8. Encourage healthy life style pattern, exercise and immunization. 
9. Treatment of obstruction by drugs.  
10. Assessment of hypoxemia, O2 therapy given if needed.  
11. Assess the response to therapy.  
12. Referral to higher centre if necessary.  
13. Patient education.  
Management of acute exacerbation:
31
  
Bronchodilators : 
Patients are treated with an inhaled agonist, often with the addition 
of an anticholinergic agent. 
  The frequency of administration depends on the severity of the 
exacerbation. 
      Patients are treated initially with nebulized therapy, as such 
treatment is often easier to administer in older patients or to those in 
respiratory distress. 
The addition of methylxanthines (such as theophylline) to this 
regimen can be considered. 
Antibiotics : 
Patients with COPD are frequently colonized with potential 
respiratory pathogens. 
  
  
 
 
47 
 
Bacteria frequently implicated in COPD exacerbations include  
 Streptococcus pneumonia 
 Haemophilus influenza       
 Moraxella catarrhalis. 
In addition, Mycoplasma pneumoniae or Chlamydia pneumoniae 
are found in 5-10% of exacerbations. 
The choice of antibiotic should be based on local patterns of 
antibiotic susceptibility of the above pathogens as well as the patient's 
clinical condition.  
Glucocorticords  
The use of glucocorticoids has been demonstrated to reduce the 
length of stay, hasten recovery, and reduce the chance of subsequent 
exacerbation or relapse for a period of up to 6 months.  
A study demonstrated that 2 weeks of glucocorticoid therapy 
produced benefit indistinguishable from 8 weeks of therapy.  
The GOLD guidelines recommend 30–40 mg of oral prednisolone 
or its equivalent for a period of 10–14 days. 
Hyperglycemia, particularly in patients with preexisting diagnosis 
of diabetes, is the most frequently reported acute complication of 
glucocorticoid treatment. 
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Oxygen   
Supplemental O2 should be supplied to keep arterial saturations 
90% 
Hypoxemic respiratory drive plays a small role in patients with 
COPD.  
Studies have demonstrated that in patients with both acute and 
chronic hypercarbia, the administration of supplemental O2 does not 
reduce minute ventilation. 
It does, in some patients, result in modest increases in arterial PCO2, 
chiefly by altering ventilation-perfusion relationships within the lung.  
This should not deter practitioners from providing the oxygen 
needed to correct hypoxemia. 
Indications for long term oxygen therapy : 
I. Continous Oxygen : 
 Resting Pa O2 of 55mm of  Hg or less or oxygen saturation of 88% 
or less. 
 Resting Pa O2 of 56-59mm Hg or oxygen saturation of 89% in the 
presence of any of the following : 
 Dependent edema suggesting cardiac failure.  
 ECG showing P pulmonale.  
 Polycythemia.  
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II.  Non continous oxygen : 
 During exercise – Resting Pa O2 of 55mm Hg or less or oxygen. 
Saturation of 88% or less with a low level of exertion.  
During Sleep : 
 Resting Pa O2  < 88% with associated complications like pulmonary 
hypertension, day time somnolence and cardiac arrythmias.  
Mechanical ventilatory support 
 When PaCO2>45 mmHg, patient is said to be in respiratory failure 
and immediate initiation of non invasive positive pressure ventilation is 
recommended. It significantly leads to a reduction in mortality rate. 
Indications for NIPPV : 
Selection Criteria : 
 Moderate to severe dyspnoea with use of acessory muscles and 
paradoxical abdominal movements.  
 Moderate to severe acidosis of PH < 7.35 and / or hypercapnia 
of Pa Co2 > 6 K pa,  45mm of Hg. 
 Respiratory rate > 25 / minute. 
Indications for invasive mechanical ventilation : 
 Unable to tolerate NIPPV or NIPPV failure.  
 Severe dyspnoea with use of accessory muscles and paradoxical 
abdominal motion.  
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 Respiratory Rate > 35 / minute. 
 Life threateing hypoxaemia. 
 Severe Acidosis PH < 7.25 and / or hypercapnia Pa Co2 > 8 k 
Pa,60mm Hg. 
 Respiratory arrest.  
 Worsening in mental status despite optimal therapy. 
 Complications like shock, hypotension.  
 Other compliations like electrolyte, imbalance, sepsis, 
pneumonia, pulmonary embolism, barotrauma, massive pleural 
effusion. 
Discharge criteria for patients with COPD exacerbations : 
 Inhaled β2 agonist therapy is required no more frequently than 
every 4 hourly.  
Patient is able to walk across the room.  
 Patient is able to eat and sleep without frequent awakening by 
breathlessness.  
 Patient has been clinically stable for 12 – 24 hours.  
 Patient and attenders understand the correct use of medicatins and 
they are confident enough to manage successfully at home.  
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Follow – up visits : 
 Done 4-6 weeks after discharge.  
 Measurement of FEV, done. 
 Reassessment of inhaler technique. 
 Understanding of treatment regimen. 
 Need for longterm O2 therapy and / or home nebulizer 
espescially for stage IV Patients.  
Prognosis of COPD : 
 If COPD is clinically evident, then the median survival period is 
only about 10 years.  
 The factors which are associated with poor prognosis are  
1. Low FEV1 
2. Presence of Cor Pulmonale 
3. Severe Breathlessness 
4. Resting Tachycardia. 
5. Hypoxemia 
6. Continuos active smoking 
7. Poor nutrition 
8. Anaemia  
9. Poor quality of life 
10. Reduced exercise tolerance 
  
 
 
52 
 
11. Frequent Acute Severe exacerbations 
12. Co-morbid illness 
13. Low DLCO 
There is also a multidimensional prognostic index – BODE Index 
which includes:  
1. Body mass index 
2. Obstructive ventilatory defect severity 
3. Dyspnoea severity  
4. Exercise capacity 
Score : 
1. 7 –  2 year mortality is 30% 
2. 5 – 6 –  2 year mortality is 15% 
3. < 5 –  2 year mortality i less than 10% 
 No drug treatment has shown to alter the natural history of COPD.  
Smoking cessation is the only intervention that can arrest the rapid 
decline in lung function.  Home Oxygen therapy can also improve the 
prognosis in patients suffering from hypoxemia. 
 The best guide to the progression of COPD is the change in FEV1, 
over time.  FEV1, declines with normal aging at about 30ml / year, but 
this decline is increased to 45ml/year in smokers. Cessation of smoking 
will produce only a small improvement in FEV1, but the subsequent fall 
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in FEV1, progressively slows to the rate of 30ml/year, as that of in non 
smokers.  
 Depending upon the diease severity, the 5 year mortality rate of 
patients with COPD is 40-70%.  The three major causes of death are 
COPD itself, Bronchogenic Carcinoma and Corpulmonale. The age and 
reduction in FEV1, are the most ommon prognostic factors.  
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MATERIALS AND METHODS 
PLACE OF STUDY 
      This study was conducted on 50 patients in the general medical ward. 
PERIOD OF STUDY 
         From  NOV 2011 to NOV2012.               
DESIGN 
Observational prospective cohort study of patients who are 
smokers admitted in the hospital for complaints other than respiratory 
symptoms. A total of 50 patients were included in the study. 
METHODOLOGY 
A. Subject selection 
1. Inclusion criteria 
a. Subjects randomly selected from medical ward in age group                      
20 -60 years. 
b. with h/o smoking of atleast on ten pack years(ie.. > 10 cigarettes 
or 20 beedies per day for atleast  ten years). 
2. Exclusion criteria 
a. Patients who had symptoms as per American 
b. Thoracic Society scale for dyspnoea 
c. Known case of cardiac disease. 
d. Known diabetic patients. 
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e. Patients with spinal deformity. 
f. Age > 60 years 
g. Women 
All patients included in the study were subject to thorough clinical 
examination. All were subject to laboratory investigation as per the 
profoma. 
UDWADIA’S FORMULA 
VARIABLES   MALE    FEMALE 
FEV 1(L)   Adults <30years    Adults <30years 
0.039×H-0.010 × A-3.266  0.025× H-0.011 × A-1.424 
Adults >30years    Adults >30years 
0.037×H-0.022× A-2.650    0.032×H-0.012×A-2.580 
FVC(L)   Adults <30years    Adults <30years 
0.055×H+0.019×A-6.058  0.030×H+0.006×A-2.284 
Adults >30years    Adults >30years 
0.054×H-0.018×A-4.832  0.043×H-0.010×A-3.755 
PEF    0.085×H-0.0187×A-6.2083  0.0497×H-0.0336×A-0.1399 
FEF25-75%  0.0173×H-0.0407×A+1.6108 0.0245×H-0.0336×A0.1399 
FEF50   0.0195×H-0.0365× A+1.7383 0.0272×H-0.279×A-0.2704 
FEF75   0.0088×H-0.0301×A+1.0402  0.0113×H-0.0288×A+0.5012 
A - Age in years, H - Height in cms 
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1 18 81.8 2 9.1 22 100.
0 27 54.0 2 4.0 50 100.
 very much declined to mild and mo
e of smokers.It is declined to a lesser ex
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Table - 13 
ction of FEF 25%-75% in relation to a
FEF 25-75% 
Total
 Mild Moderate 
 N % N % N %
0 0 .0 0 .0 12 100.
8 9 56.3 0 .0 16 100.
1 18 81.8 2 9.1 22 100.
0 27 54.0 2 4.0 50 100.
hows similar distribution as that of
oup under study. 
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Table  - 15 
d  moderate reduction  of FEF 25%-
relation to age 
FEF25-75% 
Total rmal 
Mild/ 
Moderate 
% N % N % 
 67.9 9 32.1 28 100 
2 9.1 20 90.9 22 100 
 42 29 58 50 100 
6 df=1   p<0.001 
a significant reduction in age more th
 age less than 50 years. 
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Table – 16 
Comparison  of  FEV1 reduction  in relation  to  duration  of  
smoking  in years 
 
 
Duration of 
smoking in years 
FEV1 
Total 
Normal Mild/ Moderate 
N % N % N % 
10-19 17 85.0 3 15.0 20 100.0 
20-29 4 25.0 12 75.0 16 100.0 
>30 0 .0 14 100.0 14 100.0 
Total 21 42.0 29 58.0 50 100.0 
χ
2
 =27.217 df=2   p<0.001 
 
FEV1 shows a significant reduction with prolonged duration of 
smoking. More than 30 years of smoking in this study showed significant 
airfiow Limitation  when compared with 10-19 years of smoking 
duration. 
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Table -17 
V1 reduction in relation to packyears
FEV1 
Total Normal 
Mild/ 
Moderate 
N % N % N % 
16 84.2 3 15.8 19 100
4 28.6 10 71.4 14 100
1 5.9 16 94.1 17 100
21 42 29 58 50 100
7 df=2   p<0.001 
significantly reduced in smokers > 30
mokers< 30 pack years. 
20-29 More than 30
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DISCUSSION 
 In this study, a major group about 54% showed mild obstructive 
pattern, a minor group of about 4% showed moderate obstructive pattern 
and the remaining 42% had normal lung function.  The multicentre Lung 
Health study conducted a similar randomized clinical trial by doing 
spirometry in current smokers, but without any symtoms 25% of the 
population under study had a moderate airflow obstruction and 5% had 
severe airflow limitation which was comparable to this study
44
. 
 In this study, there is a significant airflow limitation in relation to 
the age distribution and pack years of smoking. 
 In a similar study done by Dan Stanescu et al, the middle aged 
smokers are at less risk of functional detoriation, but smokers above the 
age of 50 years were at  high risk of development of COPD which was 
comparable to this study.   A similar study was done in Canada which 
also showed the prevalence of airway obstruction of about 4.6% in the 
age group of 55 – 64 years, 5% in 65 – 74 years and 6.8% in the age 
group of >75 years which was comparable to this study. 
 In this study, the mean FEV1, levels were 2.6 ± 0.6 in smokers 
with smoking history less than 12 median pack years and 1.8 ± 0.6 in 
smokers with history of smoking more than 12 pack years.  The rate of 
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decline of FEV1, is very significant with increase in the number of pack 
years. 
 Young et al, done a similar study which showed a significant 
reduction of FEV1, and he used the measure of airflow limitation to 
assess the risk of development of not only COPD, but also the risk of 
incidence of bronchogenic carcinoma, coronary arterial heart disease and 
cerebro vascular accident. 
 Fletcher CM et al also conducted a similar study in early stages of 
development of COPD, which showed that FEV1, falls gradually over 
few years in smokers which was comparable to this study.
45
 
 In this study, there is a decline of FEF 25-75% in the smokers, 
which was more in the smokers of longer pack years duration than in 
smokers  of less  pack years duration which is very significant.  FEF 25-
75% is the major predictor of small airway obstruction and therefore the 
incidence of COPD. 
 A similar study was done by Pauwells RA et al, which showed 
significant reduction in FEF 25-75% in smokers which was comparable 
to this study.
46
 
 In this study, the FEV, FVC ratio shows mild GOLD airflow 
limitation in 54% of the smokers, moderate limitation in 4% of smokers 
which is very significant. 
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 A similar study was done by Polatl Mehmet et al, where there was 
significant disease in FEV, FEV/FVC ratio and FEF 25-75%, FEF 75% 
which was comparable to this study
48
 
 In this study, there is significance with the type of smoking and 
occupation.  The cigarettes were significantly associated with Sedentary 
occupation where as Beedis were associated with heavy manual workers. 
 Both Beedis and Cigarette are associated with the development of 
COPD.  Filter tipped cigarettes are less deleterious when compared to 
Beedis. 
 Thus spirometry is a very useful screening method to detect the 
airflow limitation very earlier in the course of incidence of COPD, if it is 
done during earlier age and pack years of smoking.  Identification of even 
mild degree of air flow limitation is very significant, so that smoking 
cessation with reduce the burden of the chronic obstructive pulmonary 
disease to the society. 
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CONCLUSION 
 In this study, 42% of smoker, had normal lung function, 58% 
showed obstructive pattern in their lung functions. 
 A significant number of patients had small airway disease as 
evidenced by decreased FEF 25-75%. 
 A decline in FEV, FEV/FVC ratio were observed in 58% of 
asymptomatic smokers, who may develop obstructive lung disease in the 
near future. 
 Increasing age, increased quantum of smoking both in duration and 
number which is expressed in pack years are significant confounding 
factors in the development of airflow limitation. 
 A definitive conclusion cannot be arrived with the association of 
smoking and occupation, since only a small sample size was studied. 
 Routine lung function tests by doing spirometry in smokers without 
symptoms is an important screening test, so that the incidence of COPD 
can be detected very earlier in the course of the disease. 
 Thus spiromety is essential to detect the tip of iceberg of COPD. 
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PROFORMA 
Case No. 
Name :    Age :     Sex : 
IP No. :   DOA :    DOD: 
Address :    Occupation : 
 
FINAL DIAGNOSIS: 
H/o Hypertension 
H/o diabetes mellitus 
Past History 
IHD  TB  RHD  BA  
Personal History 
Tobacco use: Smoking Beedi/ Cigarette/ pipe / cigar 
Quantity 
Period   Other forms 
Alcohol 
GENERAL EXAMINATION 
Height   Weight    BMI 
PR :    RHYTHM :   CHARACTER : 
Temperature:   BP: 
 
  
 
 
 
 
Respiratory rate:   Type: 
Pallor:    Cyanosis: 
Lymph node:   Clubbing: 
JVP: 
RESPIRATORY SYSTEM 
UPPER RESP.TRACT:   NOSE 
 PNS 
 THROAT 
INSPECTION 
Shape of chest:   B/L Symmetrical / Not 
Trachea position:   R / Central / L 
Any spinal deformity:  Scoliosis / kyphosis / Normal 
Any chest deformity:   Hollowing / Bulging / Normal 
Movement of chest:   Equal / Not 
Any dilated veins/pulsations: Present / Not 
Any scar / sinuses :   Present / Not 
Use of accessory muscles:  Yes / No 
Intercostal retraction:   Yes / No 
Apical impulse:   Visualized / Not 
  
  
 
 
 
 
PALPATION 
Tracheal position:   R / Central / L 
Movement of chest:   Equal / Not 
Apical impulse:   Normal / Not 
MEASUREMENTS 
AP Diameter: 
Transverse diameter: 
Chest circumference: 
Expansion: 
Palpable rales/ ronchi:  Yes / No 
Site 
Percussion 
 Anteriorly 
Kronig isthmus 
Infraclavicular 
Mammary 
Liver dullness 5th ICS Yes / No 
Traube’s area Tympanic / Not 
Tidal percussion: 
 
 
  
 
 
 
 
Posteriorly 
Suprascapular: 
Infrascapular: 
Interscapular: 
Axillary: 
Infra axillary: 
AUSCULTATION 
Breath sounds -  normal / diminished 
Type -    Vesicular / Bronchovesicular / Bronchial 
Added sounds –  rales / rhonchi 
Site : 
VR    Equal / Not 
CVS 
ABDOMEN 
CNS 
Investigations : 
Blood Sugar :    URINE : 
Serum Creatinine : 
CXR PA : 
ECG : 
 
  
 
 
 
 
Echo : 
Spirometry : 
Others 
Bronchoscopy 
HRCT CHEST 
 
S.NO NAME AGE SEX OCCUPATION DURATION OF SMOKING FEV1 FEV1/FVC FEF 25%-75% PACK YEARS CIGARETTES/BIDIS
1 PONNUSAMY 40 M FARMER 20 YRS N N N 20 B
2 SUNDARAPANDI 47 M MASON 15 YRS N N N 15 B
3 ABUTHAHIR 52 M FARMER  25 YRS 1 1 1 25 B
4 SIKKANDAR 48 M FARMER 17 YRS 1 1 1 17 B
5 BABUJI 45 M MASON  23 YRS 1 1 1 23 B
6 GURUSAMI 60 M COMPOUNDER 30 YRS 1 1 1 30 C
7 KUMAR 45 M MASON 18 YRS N N N 18 C
8 ANGASELVAM 54 M FARMER 24YRS 1 1 1 24 B
9 ARUMUGAM 52 M MASON 22YRS 1 1 1 44 C
10 SENTHIL 48 M CARPENTER 24 YRS 1 1 1 24 C
11 GURUDEV 54 M FARMER 20 YRS 1 1 1 40 C
12 KUMARAVEL 45 M BUSINESS 15 YRS 1 1 1 30 C
13 MOHAMMAD 52 M BUSINESS 26 YRS 1 1 1 26 C
14 RAFIQUE 48 M EXECUTIVE 15 YRS 1 1 1 15 C
15 SUNDAR 35 M BUSINESS 10YRS N N N 10 C
16 RAJA 48 M CONDUCTOR 28 YRS N N N 28 C
17 MURUGAN 37 M MASON 17 YRS N N N 17 C
18 RAVICHANDRAN 44 M FARMER 24 YRS 1 1 1
24
B
19 SEETHARAMAN 52 M DOCTOR 40 YRS 1 1 1 40 C
20 SHELTON 35 M ENGINEER 10 YRS N N N 10 C
21 ANBALAGAN 38 M SWEEPER 18 YRS N N N 18 B
22 AYYAPAN 33 M SWEEPER 18 YRS N N N 36 B
23 SENTHIL KUMAR 37 M GROCERY 20 YRS N N N
20
C
24 KARTHICK 37 M GROCERY 18 YRS N N N 18 C
25 MAHENDRAN 52 M FARMER 28 YRS 2 2 2 42 B
26 RANGAMANI 40 M BUSINESS 12 YRS N N N 12 C
27 DAVID 34 M BUSINESS 14 YRS N N N 14 C
28 NAGARAJAN 42 M MASON 22 YRS N N N 22 B
29 SELVARAJ 32 M FARMER 10 YRS N N N 10 B
30 RAMSUNDAR 42 M FARMER 12 YRS N N N 12 C
31 NAGASUBBU 52 M GROCERY 35 YRS 2 2 2 35 C
32 PONNUSAMY 44 M MASON 10 YRS N N N 10 C
33 KARUNAS 45 M SWEEPER 14 YRS N N N 14 B
34 RAHUMAN 52 M BUSINESS 30 YRS 1 1 1 30 C
35 ILAYARAJA 45 M FARMER 18YRS N N N 18 C
36 KAMAL 43 M CARPENTER 18 YRS N N N 18 C
37 RAMAR 37 M BUSINESS 10 YRS N N N 10 C
38 GURU 55 M SWEEPER 35 YRS 1 1 1 35 B
39 SUKIRTHA RAJ 58 M SWEEPER 32 YRS 1 1 1 32 B
40 SHEIK 45 M SWEEPER 25 YRS 1 1 1 25 B
41 RAJADURAI 56 M MASON 26 YRS 1 1 1 26 C
42 GIRIDHAR 58 M BUSINESS 40 YRS 1 1 1 40 C
43 MARTHANDAM 56 M MASON 42 YRS 1 1 1 42 B
44 RAJAMANI 54 M CARPENTER 35 YRS 1 1 1 35 C
45 KUPPUSAMY 56 M BUSINESS 36 YRS 1 1 1 36 C
46 ALBERT 60 M GROCERY 38 YRS 1 1 1 38 C
47 AROCKIYASAMI 54 M FARMER 28 YRS 1 1 1 28 B
48 MURUGAN 60 M FARMER 36 YRS 1 1 1 18 C
49 KANNAN 60 M CARPENTER 40 YRS 1 1 1 20 C
50 DEVA 52 M MASON 45 YRS 1 1 1 45 B
N - Normal, 1- Mild, 2- Moderate, B-Bidis, C-Cigarretes
 

 
